Navigation Links
MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
Date:12/9/2009

Spanish Public-private Foundation for Life Sciences Research Adopts the Genedata Screener® 7.0 Data Management Platform for High Throughput and High Content Screening.

Basel, Switzerland and Granada, Spain (PRWEB) December 8, 2009 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, and Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía), today announced their collaboration in the discovery of innovative medical compounds to fight infectious diseases, cancer and immune disorders. MEDINA has licensed the Genedata Screener platform - including the modules Condoseo for dose-response curve fitting and Kinetics Analyzer for the capture of time series data - for rapid and flexible data processing, management and analysis for all of their natural product screening and lead evaluation services. Those services span a wide range of assay technologies and instrumentation, from single-plate measurements to large-scale screens.

Fundación MEDINA has emerged from the Merck Sharp and Dohme (MSD) Basic Research Center in Madrid and houses comprehensive microbial collections and natural products libraries as well as a compound profiling platform for the identification of potential risks in cardiovascular safety and drug-drug interactions. Consequently, the MEDINA research teams need to master a multitude of screening technologies and set-up modifications on a daily basis, from anti-infective or biochemical inhibition assays to dose-response assay panels for the determination of potential compound risks.

"We received a clear vote from our users to go with Genedata," said Francisco Asensio, IT manager at Fundacion MEDINA. "The Screener system is unrivaled when it comes to the flexible and efficient integration of third-party infrastructure, and the easy templating for our complex assay setups impresses our screening teams just as much as it smoothes things out for our IT support people. As we inherited a large and disparate instrument park and built our entire organization from scratch, the need to align different technologies and research groups was a top priority."

"We are proud of our relationship with MEDINA," said Dr. Othmar Pfannes, CEO of Genedata. "Screener is an exceptional product thanks to its ability to master the breadth and complexity of today's screening scenarios. Introducing this product to the thriving Spanish life science market and establishing our presence there is an exciting challenge for Genedata. We are looking forward to a dynamic partnership with Fundación MEDINA and growing our business in Spain."

About Fundación MEDINA
Created in November 2008, Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía) is a non-profit public-private partnership between Merck Sharp and Dohme de Espana S.A. (MSD), the Junta de Andalucia and the University of Granada, Spain. MEDINA focuses on 1) the discovery of innovative compounds from microbial natural products to be licensed as new leads for development by industrial companies, and 2) ADME/TOX high throughput screening platform service for the evaluation of drug candidates. www.medinaandalucia.es

About Genedata:
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, and Genedata Expressionist® make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

###

Read the full story at http://www.prweb.com/releases/Genedata_MEDINA/kinetics_assay_screening/prweb3305024.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Scientists demonstrate multibeam, multi-functional lasers
2. Forensic Scientists at Kansas City Crime Lab Release Validation Report Confirming Zygems forensicGEM(R) Kit is a Reliable, Rapid Method for Extracting DNA From Saliva
3. Biomodels Scientists Report Development of a Novel Model for Cancer Treatment-Related Fatigue
4. Scientists develop novel method to generate functional hepatocytes for drug testing
5. Harvard scientists bend nanowires into 2-D and 3-D structures
6. Scientists use math modeling to predict unknown biological mechanism of regulation
7. Weed Scientists Take Steps to Protect Rare Orchid
8. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
9. Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers
10. UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year
11. NIST scientists study how to stack the deck for organic solar power
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... SANTA MONICA, Calif. , March 22, 2017 ... Council (MassMEDIC) are proud to announce their extended partnership ... Week will be headlined by the 21 st ... UBM,s BIOMEDevice Boston, taking place May 3-4, 2017. ... with Advanced Medical Technology Association (ADVAMED) President and ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, ... their live events series, “Stem Cell Therapy: The Next Phase in the Evolution of ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... Quantum peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by ... high-pressure feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) ...
Breaking Biology Technology:
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
(Date:3/2/2017)... , March 2, 2017 Summary ... understand Perrigo and its partnering interests and activities since 2010. ... Read ... Deals and Alliance since 2010 report provides an in-depth insight ... life sciences companies. On demand company reports are ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScan® technology provides the fastest and most accurate ...
Breaking Biology News(10 mins):